Compare 10X Genomics Inc (TXG) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Xylem, Inc. — how do they compare? 10X Genomics Inc trades at $47.2 (market cap $5.48B), while Xylem, Inc. trades at $117 (market cap $28.67B). The key difference: Xylem, Inc. is far larger — about 5.2× 10X Genomics Inc's market cap, and Xylem, Inc. pays a 1.43% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TXG | XYL | |
|---|---|---|
Market Cap | $5.48B | $28.67B |
Sector | Health | Industrials |
52-Week High | $45.80 | $152.95 |
52-Week Low | $11.34 | $106.34 |
Enterprise Value | $5.02B | $29.92B |
Dividend Yield | — | 1.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
XYL trades at $117.00, down 4.71% today, amid mixed technical signals with a bullish overall trend but neutral oscillators. Fundamentally, the company shows steady revenue growth from $8.6B in 2024 to $9.04B in 2025, with net income margins improving to 10.79%. Recent earnings beats and a consistent dividend history support investor confidence, while analyst consensus leans slightly bullish with a $152.71 price target.
The outlook for XYL remains positive given its earnings momentum and strategic partnerships in water technology. Key risks include execution challenges in integrating new leadership and macroeconomic pressures on industrial spending. The stock offers potential upside to analyst targets but requires monitoring of upcoming Q2 2026 results due July 28, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
